

David M Hyman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1509656/publications.pdf>

Version: 2024-02-01

129
papers

25,649
citations

19657

61
h-index

12946

131
g-index

135
all docs

135
docs citations

135
times ranked

31358
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Resistance to Noncovalent Brutonâ€™s Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	27.0	87
2	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. <i>Nature Communications</i> , 2022, 13, 1450.	12.8	47
3	AKT mutant allele-specific activation dictates pharmacologic sensitivities. <i>Nature Communications</i> , 2022, 13, 2111.	12.8	10
4	Natural History and Characteristics of <i>ERBB2</i> -mutated Hormone Receptorâ€“positive Metastatic Breast Cancer: A Multi-institutional Retrospective Caseâ€“control Study from AACR Project GENIE. <i>Clinical Cancer Research</i> , 2022, 28, 2118-2130.	7.0	3
5	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 447-459.	7.0	22
6	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>Cancer Discovery</i> , 2021, 11, 126-141.	9.4	34
7	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
8	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.	2.0	9
9	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , 2021, 53, 1577-1585.	21.4	44
10	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. <i>Modern Pathology</i> , 2020, 33, 38-46.	5.5	373
11	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020, 6, 84.	7.1	66
12	MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. <i>Ocular Oncology and Pathology</i> , 2020, 6, 159-163.	1.0	8
13	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. <i>Cancer</i> , 2020, 126, 1274-1282.	4.1	37
14	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 194-202.	1.4	35
15	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 1624-1632.	7.0	103
16	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	18.2	29
17	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	21.4	367
18	Clinical implications of drugâ€“induced liver injury in earlyâ€“phase oncology clinical trials. <i>Cancer</i> , 2020, 126, 4967-4974.	4.1	6

#	ARTICLE	IF	CITATIONS
19	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹ Zr-Pertuzumab PET/CT. <i>Radiology</i> , 2020, 296, 370-378.	7.3	40
20	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020, 395, 1078-1088.	13.7	302
21	Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> -V600-Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020, 10, 657-663.	9.4	93
22	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology, The</i> , 2020, 21, 531-540.	10.7	608
23	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	1.2	31
24	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
25	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> -E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	7.0	54
26	Toward a More Precise Future for Oncology. <i>Cancer Cell</i> , 2020, 37, 431-442.	16.8	21
27	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. <i>Clinical Cancer Research</i> , 2020, 26, 3881-3888.	7.0	59
28	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> -Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
29	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	30.7	144
30	Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	3.0	15
31	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	27.8	295
32	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
33	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	11
34	First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 5458-5465.	7.0	47
35	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. <i>Clinical Cancer Research</i> , 2019, 25, 4712-4722.	7.0	292
36	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2019, 20, 711-718.	10.7	381

#	ARTICLE	IF	CITATIONS
37	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019, 567, 521-524.	27.8	222
38	Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. <i>JAMA Oncology</i> , 2019, 5, 570.	7.1	9
39	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven Cancer. <i>Cancer Discovery</i> , 2019, 9, 605-616.	9.4	11
40	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	6
41	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
42	A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. <i>Blood Advances</i> , 2019, 3, 934-938.	5.2	17
43	Activating mutations in <i>CSF1R</i> and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	30.7	122
44	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	27.8	1,391
45	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	30.7	485
46	Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	3.0	7
47	Next-Generation Sequencing-Based Assessment of <i>JAK2</i> , <i>PD-L1</i> , and <i>PD-L2</i> Copy Number Alterations at 9p24.1 in Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 307-317.	2.8	19
48	<i>RAF</i> inhibitor PLX8394 selectively disrupts <i>BRAF</i> dimers and <i>RAS</i> -independent <i>BRAF</i> -mutant-driven signaling. <i>Nature Medicine</i> , 2019, 25, 284-291.	30.7	125
49	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	1.4	33
50	Colorectal Carcinomas Containing Hypermethylated <i>MLH1</i> Promoter and Wild-Type <i>BRAF/KRAS</i> Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.9	112
51	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	7.0	390
52	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	27.0	2,036
53	Single-agent dabrafenib for <i>BRAF</i> ^{V600E} -mutated histiocytosis. <i>Haematologica</i> , 2018, 103, e177-e180.	3.5	40
54	A First-in-Human Phase 1 Study of LY3023414, an Oral <i>PI3K/mTOR</i> Dual Inhibitor, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3253-3262.	7.0	71

#	ARTICLE	IF	CITATIONS
55	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	27.8	572
56	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	9.4	275
57	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	16.8	589
58	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 791-798.	3.7	182
59	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	12.6	834
60	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. <i>Annual Review of Medicine</i> , 2018, 69, 319-331.	12.2	61
61	Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	3.0	2
62	BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484.	1.6	247
63	Ado-Trastuzumab Emtansine for Patients With <i>HER2</i> -Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537.	1.6	381
64	Learning All That We Can From MyPathway. <i>Journal of Clinical Oncology</i> , 2018, 36, 2450-2451.	1.6	1
65	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> ^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	3.0	20
66	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (<i>HER2</i>). <i>Science Signaling</i> , 2018, 11, .	3.6	53
67	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	9.4	138
68	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	16.8	73
69	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
70	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	7.1	132
71	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	7.0	100
72	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	21.4	411

#	ARTICLE	IF	CITATIONS
73	Clinical tumour sequencing for precision oncology: time for a universal strategy. <i>Nature Reviews Cancer</i> , 2018, 18, 527-528.	28.4	34
74	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2027-2033.	1.5	19
75	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	9.4	321
76	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1589.	7.1	139
77	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3819-3825.	8.2	45
78	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. <i>Blood</i> , 2018, 132, 49-49.	1.4	10
79	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3610-3618.	7.0	225
80	An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with <i>HER2</i> Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 575-585.	9.4	85
81	Implementing Genome-Driven Oncology. <i>Cell</i> , 2017, 168, 584-599.	28.9	405
82	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
83	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 963-972.	9.4	331
84	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	9.4	490
85	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. <i>Investigational New Drugs</i> , 2017, 35, 742-750.	2.6	10
86	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	7.0	17
87	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	2.8	96
88	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.9	58
89	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	7.4	366
90	Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1547-1551.	3.7	353

#	ARTICLE	IF	CITATIONS
91	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	7.0	161
92	Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6708-6720.	7.0	194
93	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , 2017, 21, 374-382.e4.	11.1	578
94	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	7.1	191
95	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	286
96	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	1.6	240
97	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
98	Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. <i>Journal of Clinical Oncology</i> , 2017, 35, 131-134.	1.6	6
99	Precision oncology: Charting a path forward to broader deployment of genomic profiling. <i>PLoS Medicine</i> , 2017, 14, e1002242.	8.4	16
100	Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. <i>Cancer</i> , 2016, 122, 1228-1237.	4.1	10
101	Automated eligibility screening and monitoring for genotype-driven precision oncology trials. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 777-781.	4.4	27
102	Measuring Toxicity in Phase I Clinical Trials—Letter. <i>Clinical Cancer Research</i> , 2016, 22, 1828-1828.	7.0	0
103	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹ Zr-Trastuzumab PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1523-1528.	5.0	146
104	Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 109.	2.7	19
105	Characterization of a novel germline <i>PALB2</i> duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	2.5	16
106	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016, 2, 104.	7.1	270
107	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
108	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type <i>RAS/RAF</i> . <i>Molecular Cancer Research</i> , 2016, 14, 296-301.	3.4	46

#	ARTICLE	IF	CITATIONS
109	Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 553-559.	7.0	16
110	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. <i>Oncotarget</i> , 2016, 7, 85430-85436.	1.8	60
111	Primary debulking surgery for metastatic cervical adenocarcinoma: A case report. <i>Gynecologic Oncology Reports</i> , 2015, 14, 23-25.	0.6	1
112	Tumor Genetic Screening Programs: A Call to Action. <i>Journal of Clinical Oncology</i> , 2015, 33, 2725-2726.	1.6	14
113	Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21Ådays or q28Ådays) for patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 747-755.	2.3	21
114	The role of systemic chemotherapy in the management of granulosa cell tumors. <i>Gynecologic Oncology</i> , 2015, 136, 505-511.	1.4	45
115	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	27.0	1,483
116	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. <i>Drug Discovery Today</i> , 2015, 20, 1422-1428.	6.4	136
117	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71.	9.4	115
118	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. <i>PLoS ONE</i> , 2015, 10, e0126633.	2.5	41
119	Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. <i>Oncotarget</i> , 2015, 6, 19316-19327.	1.8	13
120	Reply to M. Voskoboynik et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3199-3200.	1.6	1
121	<i>BRAF</i> V600E Mutation and Clonal Evolution in a Patient With Relapsed Refractory Myeloma With Plasmablastic Differentiation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e65-e68.	0.4	22
122	Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials. <i>Journal of Clinical Oncology</i> , 2014, 32, 519-526.	1.6	47
123	Placental site trophoblastic tumor: Analysis of presentation, treatment, and outcome. <i>Gynecologic Oncology</i> , 2013, 129, 58-62.	1.4	53
124	<i>BRAF</i> Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. <i>Cancer</i> , 2013, 119, 548-554.	4.1	169
125	Improved survival for <i>BRCA2</i> -associated serous ovarian cancer compared with both <i>BRCA</i> -negative and <i>BRCA1</i> -associated serous ovarian cancer. <i>Cancer</i> , 2012, 118, 3703-3709.	4.1	72
126	Outcomes of primary surgical cytoreduction in patients with <i>BRCA</i> -associated high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2012, 126, 224-228.	1.4	29

#	ARTICLE	IF	CITATIONS
127	Disseminated Intravascular Coagulation with Excessive Fibrinolysis in Prostate Cancer: A Case Series and Review of the Literature. <i>Oncology</i> , 2011, 81, 119-125.	1.9	45
128	Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2011, 123, 196-199.	1.4	10
129	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0